NCT00511927

Completed

Growth Hormone Deficiency in Chronic Heart Failure: an Obser...

Federico II University Source

Compare

Other study identifiers

Sponsor study identifier

GH Deficiency in CHF

Study Type

observational

Actual enrollment (reported)

250

Locations

1 country

Sites

1

Timeline

Study Start

July 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

February 2014

Actual (reported)

Study Completion

February 2014

Actual (reported)

Brief Summary

Aim of this study is to define the possible detrimental effect of a lack of growth hormone, on the well-being and life expectation of patients affected by heart failure.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 250 participants
Study completion date: February 2014
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 3, 2007
Actual (reported)
First Posted
August 6, 2007
Actual (reported)
Study Start
July 2010
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
February 2014
Actual (reported)
Study Completion
February 2014
Actual (reported)

Last Updated: February 20, 2014
Status Verified: February 2014
Last Update Submitted: February 18, 2014

Conditions

Cardiomyopathy Growth Hormone Deficiency Heart Failure Ischemic Heart Disease

Keywords

heartfailuregrowthhormoneigfdilativecardiomyopathy

Outcome Measures

Primary Outcomes (1)

overall survival
3 years

Study Arms (2)

GHD

Patients with Growth Hormone Deficiency

non-GHD

Patients with CHF, without coexisting growth hormone deficiency

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with chronic heart failure due to left ventricular systolic dysfunction

You may qualify if:

Diagnosis of Heart Failure: NYHA class II to IV, ACC/AHA stage C/D

Sponsors & Collaborators

Federico II University
Otherlead

Study Sites (1)

III Medicina Interna - Federico II University

Naples, 80100, Italy

Biospecimen

Retention: SAMPLES WITHOUT DNA

Sera of the patients at time-points upon recruitment and after 12 months

MeSH Terms

Conditions

Myocardial IschemiaCardiomyopathiesHeart FailureDwarfism, Pituitary

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular DiseasesDwarfismBone Diseases, DevelopmentalBone DiseasesMusculoskeletal DiseasesBone Diseases, EndocrineHypopituitarismPituitary DiseasesHypothalamic Diseases

Study Officials

Antonio Cittadini, MD
Federico II University
STUDY DIRECTOR
Luigi Saccà, MD
Federico II University
STUDY CHAIR

Enrollment

250 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor of Internal Medicine

Study Record Dates

First Submitted

August 3, 2007

First Posted

August 6, 2007

Study Start

July 2010

Date type not reported

This date has not been verified as actual or estimated.

NCT01102140

The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

Phase 2Terminated

NCT02976350

Hormone Deficiency in Heart Failure With Preserved Ejection Fraction

Completed

NCT00759811

METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)

Phase 2/3Completed

NCT02827799

Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure

Not ApplicableCompleted

NCT01178528

Heart Rate Reduction in Heart Failure

Phase 3Completed

NCT00696410

The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy

Phase 1Completed

Left ventricular end diastolic diameter \>60 mm

Left ventricular ejection fraction \< 40%

Clinical stability, guideline-oriented top pharmacological therapy

Informed consent

You may not qualify if:

Active Myocarditis
Hypertrophic Cardiomyopathy
Active endocarditis
Active malignancy
End stage renal disease
Severe liver disease (Child B-C)

Contact the study team to confirm eligibility.

Brain Diseases

Central Nervous System Diseases

Nervous System Diseases

Endocrine System Diseases

Primary Completion

February 2014

Actual (reported)

Study Completion

February 2014

Actual (reported)

Last Updated

February 20, 2014

Record last verified: 2014-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00511927
Data provider: ClinicalTrials.gov
Source updated: 2014-02-20
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:18:41 UTC

Locations

IT(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

GHD

non-GHD

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations